Patents by Inventor William W. Turner, Jr.
William W. Turner, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11814376Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.Type: GrantFiled: January 4, 2021Date of Patent: November 14, 2023Assignees: Assembly Biosciences, Inc., Indiana University Research and Technology CorporationInventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
-
Publication number: 20230044112Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.Type: ApplicationFiled: January 4, 2021Publication date: February 9, 2023Applicants: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
-
Publication number: 20230019129Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.Type: ApplicationFiled: January 21, 2021Publication date: January 19, 2023Applicants: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.Inventors: William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
-
Patent number: 11078170Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.Type: GrantFiled: March 1, 2018Date of Patent: August 3, 2021Assignee: Assembly Biosciences, Inc.Inventors: William W. Turner, Jr., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
-
Patent number: 10987360Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.Type: GrantFiled: September 14, 2017Date of Patent: April 27, 2021Assignee: Assembly Biosciences, Inc.Inventors: William W. Turner, Jr., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
-
Patent number: 10968211Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.Type: GrantFiled: May 30, 2019Date of Patent: April 6, 2021Assignees: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
-
Patent number: 10947224Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.Type: GrantFiled: April 27, 2018Date of Patent: March 16, 2021Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.Inventors: William W. Turner, Jr., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
-
Publication number: 20200157070Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.Type: ApplicationFiled: March 1, 2018Publication date: May 21, 2020Inventors: William W. Turner, JR., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
-
Publication number: 20200131168Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.Type: ApplicationFiled: May 30, 2019Publication date: April 30, 2020Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
-
Publication number: 20190255067Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.Type: ApplicationFiled: September 14, 2017Publication date: August 22, 2019Inventors: William W. Turner, JR., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
-
Patent number: 10273228Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.Type: GrantFiled: April 15, 2016Date of Patent: April 30, 2019Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.Inventors: Lee Daniel Arnold, Hans Maag, William W. Turner, Jr.
-
Patent number: 10220034Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.Type: GrantFiled: October 16, 2014Date of Patent: March 5, 2019Assignee: Indiana University Research and Technology CorporationInventors: Adam Zlotnick, Lichun Li, William W. Turner, Jr., Samson Francis
-
Patent number: 10183936Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.Type: GrantFiled: March 13, 2015Date of Patent: January 22, 2019Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.Inventors: William W. Turner, Jr., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
-
Publication number: 20180273521Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.Type: ApplicationFiled: April 27, 2018Publication date: September 27, 2018Applicants: Indiana University Research and Technology Corporationt, Assembly Biosciences, Inc.Inventors: William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
-
Publication number: 20180099952Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.Type: ApplicationFiled: April 15, 2016Publication date: April 12, 2018Applicants: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.Inventors: Lee Daniel Arnold, Hans Maag, William W. Turner, Jr.
-
Patent number: 9796722Abstract: Novel virus assembly effector compounds having a therapeutic effect against Hepatitis B viral infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed are pharmaceutical compositions including the disclosed compounds, methods of treatment of HBV infection, and a process to synthesize the disclosed compounds.Type: GrantFiled: October 14, 2016Date of Patent: October 24, 2017Assignee: Indiana University Research and Technology CorporationInventors: Adam Zlotnick, Lichun Li, William W. Turner, Jr.
-
Publication number: 20170015658Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.Type: ApplicationFiled: March 13, 2015Publication date: January 19, 2017Inventors: William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
-
Publication number: 20160271130Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.Type: ApplicationFiled: October 16, 2014Publication date: September 22, 2016Applicant: Indiana University Research and Technology Corp.Inventors: Adam Zlotnick, Lichun Li, William W. Turner, Jr., Samson Francis
-
Patent number: 6916784Abstract: Provided are compounds of the formula (1): wherein R? is hydrogen, methyl or NH2C(O)CH2—; R? and R?? are independently methyl or hydrogen; R adn Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R?H) forms of the compounds.Type: GrantFiled: February 27, 2003Date of Patent: July 12, 2005Assignee: Eli Lilly and CompanyInventors: Frederick J. Burkhardt, Manuel Debono, Jeffrey S. Nissen, William W. Turner, Jr.
-
Patent number: 6743777Abstract: Provided are compounds of the formula (1): wherein R′ is hydrogen, methyl or NH2C(O)CH2—; R″ and R′″ are independently methyl or hydrogen; R adn Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.Type: GrantFiled: February 27, 2002Date of Patent: June 1, 2004Assignee: Eli Lilly and CompanyInventors: Frederick J. Burkhardt, Manuel Debono, Jeffrey S. Nissen, William W. Turner, Jr.
